Physical Characterization of the “Immunosignaturing Effect”*

Identifying new, effective biomarkers for diseases is proving to be a challenging problem. We have proposed that antibodies may offer a solution to this problem. The physical features and abundance of antibodies make them ideal biomarkers. Additionally, antibodies are often elicited early in the ontogeny of different chronic and infectious diseases. We previously reported that antibodies from patients with infectious disease and separately those with Alzheimer's disease display a characteristic and reproducible “immunosignature” on a microarray of 10,000 random sequence peptides. Here we investigate the physical and chemical parameters underlying how immunosignaturing works. We first show that a variety of monoclonal and polyclonal antibodies raised against different classes of antigens produce distinct profiles on this microarray and the relative affinities are determined. A proposal for how antibodies bind the random sequences is tested. Sera from vaccinated mice and people suffering from a fugal infection are individually assayed to determine the complexity of signals that can be distinguished. Based on these results, we propose that this simple, general and inexpensive system could be optimized to generate a new class of antibody biomarkers for a wide variety of diseases.

[1]  R Hal Scofield,et al.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus. , 2003, The New England journal of medicine.

[2]  C. Baggiani,et al.  Affinity between immobilised monoclonal and polyclonal antibodies and steroid-enzyme tracers increases sharply at high surface density , 1999 .

[3]  J. Clements,et al.  Differential Biological and Adjuvant Activities of Cholera Toxin and Escherichia coli Heat-Labile Enterotoxin Hybrids , 2001, Infection and Immunity.

[4]  F. Frueh,et al.  REVIEWTHEME : GENERAL Integration and use of biomarkers in drug development , regulation and clinical practice : a US regulatory perspective , 2008 .

[5]  S. Hanash,et al.  Disease proteomics , 2003, Nature.

[6]  P. Lipsky,et al.  Autoantibodies as predictors of disease. , 2001, The Journal of clinical investigation.

[7]  R. Sitia,et al.  Managing and exploiting stress in the antibody factory , 2007, FEBS letters.

[8]  Abner Louis Notkins,et al.  Polyreactivity of antibody molecules. , 2004, Trends in immunology.

[9]  S. Kaveri,et al.  Heterogeneous antigen recognition behavior of induced polyspecific antibodies. , 2010, Biochemical and biophysical research communications.

[10]  L. Wahl,et al.  The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. , 2007, Cell host & microbe.

[11]  Phillip Stafford,et al.  A general method for characterization of humoral immunity induced by a vaccine or infection. , 2010, Vaccine.

[12]  Lloyd J. Old,et al.  A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.

[13]  A. Jesaitis,et al.  Phage Display Epitope Mapping of Human Neutrophil Flavocytochromeb 558 , 2001, The Journal of Biological Chemistry.

[14]  P. Stafford,et al.  Three methods for optimization of cross-laboratory and cross-platform microarray expression data , 2007, Nucleic acids research.

[15]  Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels , 2009 .

[16]  Hanspeter Herzel,et al.  Identification of distinct antibody epitopes and mimotopes from a peptide array of 5520 randomly generated sequences. , 2002, Journal of immunological methods.

[17]  K. Rajewsky,et al.  Homeostasis of Peripheral B Cells in the Absence of B Cell Influx from the Bone Marrow , 2001, The Journal of experimental medicine.

[18]  A. Jesaitis,et al.  Phage display epitope mapping of human neutrophil flavocytochrome b558. Identification of two juxtaposed extracellular domains. , 2001, The Journal of biological chemistry.

[19]  Phillip Stafford,et al.  Discovery of High-Affinity Protein Binding Ligands – Backwards , 2010, PloS one.

[20]  M. Atkinson,et al.  Autoantigens IA-2 and GAD in Type I (insulin-dependent) diabetes , 1999, Diabetologia.

[21]  T. Bein,et al.  Surface reactions on thin layers of silane coupling agents , 1993 .

[22]  S. Gultekin,et al.  Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. , 2000, Brain : a journal of neurology.

[23]  Erkki Ruoslahti,et al.  Organ targeting In vivo using phage display peptide libraries , 1996, Nature.

[24]  J L van Hemmen,et al.  Memory in idiotypic networks due to competition between proliferation and differentiation. , 1993, Bulletin of mathematical biology.

[25]  Yoram Louzoun,et al.  A Systems Immunology Approach to the Host-Tumor Interaction: Large-Scale Patterns of Natural Autoantibodies Distinguish Healthy and Tumor-Bearing Mice , 2009, PloS one.

[26]  R. Darnell,et al.  Paraneoplastic syndromes involving the nervous system. , 2003, The New England journal of medicine.

[27]  Robert J. Neely,et al.  Cell Division Rates of Primary Human Precursor B Cells in Culture Reflect In Vivo Rates , 2004, Stem cells.

[28]  K. Rajewsky,et al.  The bulk of the peripheral B-cell pool in mice is stable and not rapidly renewed from the bone marrow. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Johnston,et al.  Screening the whole genome of a pathogen in vivo for individual protective antigens. , 2005, Vaccine.

[30]  Phillip Stafford,et al.  Application of immunosignatures to the assessment of Alzheimer's disease , 2011, Annals of neurology.

[31]  N. Murray,et al.  Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[32]  E. Bonifacio,et al.  Maturation of the humoral autoimmune response to epitopes of GAD in preclinical childhood type 1 diabetes. , 2000, Diabetes.

[33]  R. Voltz Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy , 2002, The Lancet Neurology.

[34]  D. Tang,et al.  Genetic immunization is a simple method for eliciting an immune response , 1992, Nature.

[35]  Volker Stadler,et al.  High-density peptide arrays. , 2009, Molecular bioSystems.

[36]  Joseph Barten Legutki,et al.  Evaluation of Biological Sample Preparation for Immunosignature-Based Diagnostics , 2012, Clinical and Vaccine Immunology.

[37]  J. Yates,et al.  Biomarkers for Early and Late Stage Chronic Allograft Nephropathy by Proteogenomic Profiling of Peripheral Blood , 2009, PloS one.

[38]  Phillip Stafford,et al.  Exploring Antibody Recognition of Sequence Space through Random-Sequence Peptide Microarrays , 2010, Molecular & Cellular Proteomics.

[39]  M. Lehtinen,et al.  Stability over time of serum antibody levels to human papillomavirus type 16. , 1998, The Journal of infectious diseases.